PET-CT DIAGNOSIS OF CARCINOMA PROSTATICO WITH ALTERNATIVE TO FLUORODESOSSIGLUCOSIO Radio: 18F-COLINA - ND

• Conditions: Prostate cancer

• Registration Number: EUCTR2008-004236-20-IT
• Lead Sponsor: AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-03-24
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients with histological diagnosis of early prostate cancer, surgically treated with radical intent, which, after a month after, we have not observed the reset of PSA (> 0.2 ng / ml, but not> 2 ng / ml ).
2nd Patients with histological diagnosis of early prostate cancer, surgically treated with radical intent with zero PSA after 1 month, which is a documented biochemical recurrence with PSA values> 0.2 and <2 ng / ml, allowing a subsequent radiotherapy in rescue.
3rd Patients with histological diagnosis of prostate cancer early, to be treated with radiotherapy with radical intent, to define the Biological Target Volume
4th Patients with histological diagnosis of early prostate cancer treated with radiotherapy with radical intent, which, after 18 months, after reaching the nadir, the PSA shows an increase> 2 ng / ml.
5th Patients with histological diagnosis of early prostate cancer, already treated with radical intent with surgery or radiotherapy and / or hormonal therapy, with bone scintigraphy and / or abdominal and pelvic CT showing a situation of oligometastatizzazione, in which case the PET-CT with choline defining the actual extent of metastasis, for proper selection of patients by radiation therapy to address in order to prolong and improve the survival with no macroscopic disease.
6th Staging of disease highly aggressive prostate cancer (Gleason> 7). The data emerging in the literature survey PET-CT with 18F-choline appears to have in these patients a higher sensitivity than conventional all`imaging.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients outside indication

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified